AVM
Arch Venture Management Portfolio holdings
AUM
$299M
This Quarter Return
+5.62%
1 Year Return
-19.47%
3 Year Return
-31.35%
5 Year Return
–
10 Year Return
–
AUM
$299M
AUM Growth
+$299M
(+45%)
Cap. Flow
+$81.2M
Cap. Flow
% of AUM
27.15%
Top 10 Holdings %
Top 10 Hldgs %
99.93%
Holding
11
New
2
Increased
1
Reduced
–
Closed
–
Top Buys
| 1 |
Vir Biotechnology
VIR
|
$65.1M |
| 2 |
Lyell Immunopharma
LYEL
|
$16.1M |
| 3 |
CERo Therapeutics
CERO
|
$2.76K |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Beam Therapeutics
BEAM
$1.66B
| $77.2M | 25.82% | 4,540,132 | – | – |
|
|
2
Vir Biotechnology
VIR
$686M
| $65.1M | 21.76% | +12,916,663 | New | +$65.1M |
|
|
MAZE
3
Maze Therapeutics, Inc. Common Stock
MAZE
$635M
| $50.6M | 16.91% | 4,120,053 | – | – |
|
|
RAPP
4
Rapport Therapeutics
RAPP
$643M
| $42.4M | 14.19% | 3,728,738 | – | – |
|
|
VERV
5
DELISTED
Verve Therapeutics
VERV
| $22.6M | 7.54% | 2,008,809 | – | – |
|
|
6
Lyell Immunopharma
LYEL
$213M
| $16.1M | 5.39% | +1,820,634 | New | +$16.1M |
|
7
Erasca
ERAS
$445M
| $14.1M | 4.71% | 11,055,554 | – | – |
|
8
Gossamer Bio
GOSS
$562M
| $9.91M | 3.31% | 8,055,916 | – | – |
|
9
Q32 Bio
QTTB
$20.9M
| $478K | 0.16% | 320,482 | – | – |
|
|
UBX
10
DELISTED
Unity Biotechnology
UBX
| $386K | 0.13% | 1,004,817 | – | – |
|
|
11
CERo Therapeutics
CERO
$9.06M
| $216K | 0.07% | 22,389 +287 | +1% | +$2.76K |
|